Real-World Evidence on Healthcare Resource use and Associated Cost With Multiple Myeloma in The Netherlands

Blommestein, Hedwig M.; Verelst, SG; Zagorska, A; Stevanović, Jelena; Engström, Åsa; Sonneveld, Pieter; Pc, Huijgens; Lefèvre, Cinira; Groot, CA Uyl-de

doi:10.1016/j.jval.2016.09.2311

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These guidelines predominantly advocate for proteasome inhibitor-based therapies, as they offer superior response rates and improved survival outcomes, alongside the use of thalidomide, melphalan, lenalidomide, and cyclophosphamide [14]. In comparison to cost estimates from other countries, the monthly cost per patient for therapy medications alone in Singapore is higher than those reported in China [15], The Netherlands [16], and Germany [17], but considerably lower than the costs in the United States [18,19], which are nearly double. Several factors contribute to these variations.…”

Section: Discussionmentioning

confidence: 99%

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Bayani,

Lin,

Ooi

et al. 2023

eJHaem

View full text Add to dashboard Cite

Multiple myeloma, a hematological malignancy, imposes a significant financial burden on healthcare systems. Health technology assessments (HTA) and economic evaluations play vital roles in reimbursement decisions and cost containment. This study aimed to explore healthcare utilization patterns and costs among myeloma patients in Singapore through a retrospective analysis of 605 patients treated at two cancer centers. Data encompassing demographics, treatment utilization, and billing were extracted from electronic records, and a cost analysis was performed from the perspective of the Singapore healthcare system. The results revealed common usage of immunomodulatory agents (52%) and proteasome inhibitors (37%), with bortezomib being the most frequently used targeted treatment. Treatment costs increased with disease progression, displaying variations depending on the therapeutic agent used. Notably, hospitalization costs due to adverse events were substantial, with pneumonia as the leading cause. This study highlights the high cost of myeloma therapy in Singapore, posing a financial burden for households. Findings may inform economic evaluations, evidence generation, reimbursement, and subsidy decisions. Leveraging real‐world data from electronic records provides valuable insights into local healthcare utilization patterns. Future studies may explore integrating billing databases with clinical repositories for a more comprehensive analysis, and consider limitations such as incomplete clinical information and potential selection bias.

show abstract

Section: Discussionmentioning

confidence: 99%

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Bayani,

Lin,

Ooi

et al. 2023

eJHaem

View full text Add to dashboard Cite

show abstract

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

et al. 2022

View full text Add to dashboard Cite

Background Real-world data on health care resource utilisation (HCRU) and costs for French patients with multiple myeloma (MM) are limited due to the quickly evolving MM treatment landscape. This retrospective, national-level study quantified the MM economic burden in France. Methods The study included patients with newly diagnosed MM from the Système National des Données de Santé coverage claims database between 2013 and 2018 who received active treatment within 30 days of diagnosis. HCRU included hospitalisations, drugs, consultations, procedures, tests, devices, transport, and sick leave. Costs were annualized to 2019 prices. Drug treatments, reported by line of therapy (LOT), were algorithmically defined using drug regimen, duration of therapy, and gaps between treatments. Analyses were stratified by stem cell transplantation status and LOT. Results Among 6413 eligible patients, 6229 (97.1%) received ≥ 1 identifiable LOT; most received 1 (39.8%) or 2 LOT (27.5%) during follow-up. Average annual hospitalisation was 6.3 episodes/patient/year (median duration: 11.6 days). The average annual cost/patient was €58.3 K. Key cost drivers were treatment (€28.2 K; 39.5% of total HCRU within one year of MM diagnosis) and hospitalisations (€22.2 K; 48.6% of total HCRU costs in first year). Monthly treatment-related costs increased from LOT1 (€2.447 K) and LOT5 + (€7.026 K); only 9% of patients received LOT5 + . At LOT4 + , 37 distinct regimens were identified. Hospitalisation costs were higher in patients with stem cell transplantation than total population, particularly in the first year. Conclusions This study showed a high economic burden of MM in France (€72.37 K/patient/year in the first year) and the diversity of regimens used in late-line treatments.

show abstract

Real-World Evidence on Healthcare Resource use and Associated Cost With Multiple Myeloma in The Netherlands

Cited by 2 publications

References 0 publications

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore

Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study

Contact Info

Product

Resources

About